Yadav Ritu, Savant Sia, Prakash Meghana, Waraich H, Sawant Abhishek C
Midwestern University GME Consortium/Verde Valley Medical Center.
Structural Heart and Interventional Cardiology, University of Arizona School of Medicine, DHMG Cardiology- Chandler, Chandler, USA.
J Geriatr Cardiol. 2025 Jul 28;22(7):648-655. doi: 10.26599/1671-5411.2025.07.007.
Transcatheter left atrial appendage occlusion (LAAO) has become a suitable alternative to anticoagulation in patients with atrial fibrillation (AF). However, outcomes among patients age > 75 years undergoing LAAO are lacking.
We included 723 consecutive patients with AF undergoing LAAO from August 2015 to March 2020. Patient data including clinical, laboratory, procedural characteristics, medications and outcomes were collected. The primary composite outcome was major adverse cardiac events (MACE) including mortality, stroke, bleeding and readmissions at 60-days.
Mean age was 75 ± 8 years and 434 (60%) were males. Median CHADS-VASc score was 4 (IQR: 4, 5) points and median HASBLED score was 4 (IQR: 3, 4) points. Composite MACE outcome was significantly higher among patients age > 75 years in both unadjusted (17.1% 11.5%, = 0.03) and adjusted (Odds Ratio = 1.59, 95% CI: 1.02 - 2.46, = 0.04) analysis. Composite MACE was primarily driven by higher all-cause mortality (1.3% 0, = 0.04) among patients age > 75 years. The secondary outcome of procedural success was also lower among patients age > 75 years (92.2% 96.2%, = 0.02). The occurrence of stroke ( = 0.38), major bleeding ( = 0.29) and readmissions ( = 0.15) did not differ between patients age > 75 years and less than 75 years.
Patients age >75 years undergoing LAAO have worse outcomes primarily driven by higher all-cause mortality and are less likely to achieve procedural success. Future prospective studies evaluating these findings are warranted.
经导管左心耳封堵术(LAAO)已成为心房颤动(AF)患者抗凝治疗的合适替代方案。然而,年龄>75岁的患者接受LAAO治疗的结果尚缺乏相关研究。
我们纳入了2015年8月至2020年3月期间连续723例接受LAAO治疗的AF患者。收集患者的临床、实验室、手术特征、用药情况及治疗结果等数据。主要复合结局为60天时的主要不良心脏事件(MACE),包括死亡、卒中、出血及再入院。
平均年龄为75±8岁,男性434例(60%)。CHADS-VASc评分中位数为4分(四分位间距:4,5),HASBLED评分中位数为4分(四分位间距:3,4)。在未调整分析(17.1%对11.5%,P = 0.03)和调整分析(比值比 = 1.59,95%置信区间:1.02 - 2.46,P = 0.04)中,年龄>75岁的患者复合MACE结局显著更高。年龄>75岁的患者中,复合MACE主要由全因死亡率较高(1.3%对0,P = 0.04)所致。年龄>75岁的患者手术成功率这一次要结局也较低(92.2%对96.2%,P = 0.02)。年龄>75岁和<75岁的患者之间,卒中(P = 0.38)、大出血(P = 0.29)及再入院(P = 0.15)的发生率无差异。
年龄>75岁的患者接受LAAO治疗结局较差,主要原因是全因死亡率较高,且手术成功可能性较小。有必要开展未来前瞻性研究以评估这些发现。